Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Chiglitazar - Chipscreen Biosciences

Drug Profile

Chiglitazar - Chipscreen Biosciences

Alternative Names: Bilopine/Bilessglu; Carfloglitazar - Chipscreen Biosciences; Carfloglitazar sodium - Chipscreen Biosciences; Chiglitazar sodium - Chipscreen Biosciences; CS-038

Latest Information Update: 03 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chipscreen Biosciences
  • Class Aniline compounds; Antidementias; Antihyperglycaemics; Carbazoles; Fluorobenzenes; Hepatoprotectants; Phenyl ethers; Propionic acids; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase II Non-alcoholic steatohepatitis
  • Discontinued Parkinson's disease

Most Recent Events

  • 18 Mar 2024 Chipscreen Biosciences completes a phase II clinical trial for Non-alcoholic steatohepatitis in China (NCT05193916)
  • 18 Mar 2024 Efficacy and adverse event data from a phase II trial in Non-alcoholic steatohepatitis released by Chipscreen Biosciences
  • 21 Mar 2023 Chipscreen Biosciences completes a phase I trial (In volunteers) in China (PO) (NCT05681273)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top